 |
|
Older medication may be more cost-effective for some patients with schizophrenia
December 01, 2006A new study analyzing the economic implications of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) concludes that the older (first generation) antipsychotic medication perphenazine was less expensive and no less effective than the newer (second generation) medications used in the trial during initial treatment, suggesting that older antipsychotics still have a role in treating schizophrenia. The study, published in the American Journal of Psychiatry on December 1, 2006, was funded by the National Institutes of Health's National Institute of Mental Health (NIMH).
The $42.6 million CATIE trial aimed to help doctors and the 2.4 million Americans who suffer from chronic schizophrenia tailor treatments to individual needs. It is the first study to directly compare several second generation antipsychotic medications and a representative first generation antipsychotic medication.
"The results from CATIE should encourage doctors to reconsider the use of perphenazine as another choice for patients with schizophrenia," said NIMH Director Thomas Insel, M.D.
More than 90 percent of antipsychotic prescriptions are written for second generation medications, despite the fact they are more expensive than the first generation agents used to treat schizophrenia. The majority of clinicians have traditionally believed that the newer antipsychotics are more effective and better tolerated than older agents, and many experts argued that these advantages justified the difference in cost.
Robert Rosenheck, M.D., of Yale University, and colleagues analyzed costs and quality-of-life factors associated with each of the five medications used in Phase 1 of the CATIE trial-olanzapine, quietapine, risperidone, ziprasidone, and perphenazine. They found that total monthly health costs, a figure that includes both average medication costs and inpatient and outpatient costs, were up to 30 percent lower for those taking the perphenazine than for those taking the second generation medications. In addition, the researchers found no statistically significant difference in overall effectiveness between perphenazine and the second generation antipsychotics, with regard to symptom relief and side effect burden.
The findings echo what was implied in the results of the first phase of CATIE, expanding the treatment options for patients with schizophrenia. It casts doubt on the notion that the second generation antipsychotics are better than the first generation antipsychotics, and suggests that perphenazine and other first generation antipsychotics may be just as beneficial for some patients.
Still, several conditions of CATIE limit any firm conclusions about perphenazine's perceived advantages. Not all patients respond the same to different medications. In addition, the study lasted 18 months-long enough to determine how patients respond to and initially tolerate the drugs, but not long enough to consider some serious long-term side effects, such as development of the movement disorder tardive dyskinesia (TD), diabetes, cardiovascular problems, or other medical conditions that can develop even years after a patient with chronic schizophrenia starts taking an antipsychotic medication. Despite these caveats, the study results suggest new ways of thinking about medication treatments for schizophrenia.
"These results encourage doctors to revisit the older medication as an alternative, especially if a treatment change is warranted," said Dr. Rosenheck. "By showing that perphenazine and possibly other older antipsychotics may be on equal footing with the second generation antipsychotics, CATIE has opened the door to more choice in treatment options."
NIH/National Institute of Mental Health
More than 90 percent of antipsychotic prescriptions are written for second generation medications, despite the fact they are more expensive than the first generation agents used to treat schizophrenia. The majority of clinicians have traditionally believed that the newer antipsychotics are more effective and better tolerated than older agents, and many experts argued that these advantages justified the difference in cost.
Robert Rosenheck, M.D., of Yale University, and colleagues analyzed costs and quality-of-life factors associated with each of the five medications used in Phase 1 of the CATIE trial-olanzapine, quietapine, risperidone, ziprasidone, and perphenazine. They found that total monthly health costs, a figure that includes both average medication costs and inpatient and outpatient costs, were up to 30 percent lower for those taking the perphenazine than for those taking the second generation medications. In addition, the researchers found no statistically significant difference in overall effectiveness between perphenazine and the second generation antipsychotics, with regard to symptom relief and side effect burden.
The findings echo what was implied in the results of the first phase of CATIE, expanding the treatment options for patients with schizophrenia. It casts doubt on the notion that the second generation antipsychotics are better than the first generation antipsychotics, and suggests that perphenazine and other first generation antipsychotics may be just as beneficial for some patients.
Still, several conditions of CATIE limit any firm conclusions about perphenazine's perceived advantages. Not all patients respond the same to different medications. In addition, the study lasted 18 months-long enough to determine how patients respond to and initially tolerate the drugs, but not long enough to consider some serious long-term side effects, such as development of the movement disorder tardive dyskinesia (TD), diabetes, cardiovascular problems, or other medical conditions that can develop even years after a patient with chronic schizophrenia starts taking an antipsychotic medication. Despite these caveats, the study results suggest new ways of thinking about medication treatments for schizophrenia.
"These results encourage doctors to revisit the older medication as an alternative, especially if a treatment change is warranted," said Dr. Rosenheck. "By showing that perphenazine and possibly other older antipsychotics may be on equal footing with the second generation antipsychotics, CATIE has opened the door to more choice in treatment options."
NIH/National Institute of Mental Health
Antipsychotics Current Events and Antipsychotics News RSSDelirium in hospitalized adults: Situation critical, no relief available
Every year as many as seven million adults in the United States experience delirium during hospitalization.
Antipsychotic drugs double risk of death among Alzheimer's patients
New research into the effects of antipsychotic drugs commonly prescribed to Alzheimer's patients concludes that the medication nearly doubles risk of death over three years.
Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH).
First generation antipsychotic drugs as effective as newer ones in some children
Nearly every child who receives an antipsychotic medicine is first prescribed one of the second-generation, or "atypical" drugs, such as olanzapine and risperidone. However, there has never been evidence that these drugs are more effective than the older, first-generation medications.
Risks and benefits of antipsychotics in children and adolescents
Many of the psychiatric disorders observed in adults have their onset in childhood or adolescence. In fact some studies show that at least 20% of children and adolescents will fulfil a diagnostic criterion for a mental disorder before reaching adulthood.
Looking beyond the drug receptor for clues to drug effectiveness
Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.
Violence declines with medication use in some with schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Treatment With An Antipsychotic Drug Found To Cause Changes In Metabolism Earlier Than Expected
Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.
New treatment mechanisms for schizophrenia
The field of schizophrenia research has come alive with many exciting new potential approaches to treatment. From the introduction of chlorpromazine to the current day, all treatments approved by the U.S. Food and Drug Administration have had, at their core, a single treatment mechanism, the blockade of the dopamine D2 receptor.
More Antipsychotics Current Events and Antipsychotics News Articles
 |
Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd edition (Essential Psychopharmacology Series) by Stephen M. Stahl (Author) Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr. Stephen M. Stahl has revised chapters covering antipsychotics and mood stabilizers for this third edition of Antipsychotics and Mood Stabilizers. More than one-third longer than the previous edition, Antipsychotics and Mood Stabilizers is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. This updated edition includes advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics not covered in the previous edition. Intended as a primer text covering all... |
 |
Higher or Lower: Dosing Issues in the Use of Atypical Antipsychotics In spite of the great deal of clinical and basic research, the dosing strategies for atypical antipsychotics still lack a firm rational basis. The manufacturers of atypical antipsychotics recommend ranges (in mg/day) within which the products are supposed to be safe and effective. The selection of the individual patients dose within (or outside) these ranges is up to clinical judgment that should, theoretically, strike the optimal balance between the therapeutic and adverse effects. In practical terms, clinical judgment is difficult to define, and quality is hard to assess. This program will review the dosing and plasma levels of the atypical antipsychotics. |
 |
The Effects Of Anti-Psychotic Medication Forced Upon The Unfortunate Souls Who May Or May Not Need T Lafcadio (Primary Contributor) |
 |
Promoting Wellness: Schizophrenia (Online Tutorial for Institutions) by Adrianne Avillion and Mary Dreher, Educational Global Technologies, Inc. The goal of the online tutorial Promoting Wellness: Schizophrenia is to help healthcare professionals recognize this disorder and its impact on clients, families, and the community, and to promote treatment strategies that enhance the health and wellness of clients dealing with this disorder. This online tutorial is approved for continuing education. |
 |
America Fooled: The Truth About Antidepressants, Antipsychotics And How We've Been Deceived by Timothy Scott (Author) America Fooled is the non-sensational, fact-filled story of how Americans have come to believe that depression and other mental problems are caused by chemical imbalances which can be fixed with pills. It reveals how the drug studies used to achieve FDA approval are designed, paid for and written by the drug companies themselves and are purposely deceptive. Part 1 of America Fooled is focused on antidepressants, their effectiveness, and their side effects including the permanent brain damage that results from long-term use about which so few Americans have any knowledge (including those who prescribe and those who take antidepressants). Part 2 deals with the various approaches used throughout history to treat more serious mental problems including the use of antipsychotics. The side... |
 |
Stahl's Illustrated Antipsychotics by Stephen M. Stahl (Author) All of the titles in the Stahl's Illustrated Series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, Third Edition and The Prescriber's Guide. The texts in this user-friendly series can be supplements to figures, images, and tables. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Within each book, each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities. Novices may want to approach Stahl's Illustrated Series by first... |
 |
Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series) by Stephen M. Stahl (Author), Nancy Munter (Illustrator) Drawn from the best-selling second edition of Essential Psychopharmacology, Steve Stahl has revised and updated the chapters covering antipsychotics and mood stabilizers in this separate volume. This new book covers the many dimensions of psychosis, particularly as associated with schizophrenia, and examines the role of dopamine in psychosis along with the various theories about the causes, pathophysiology, and treatment of schizophrenia. New material includes discussion of a promising new agent, aripiprazole, the first in a new class of dopamine stabilizers; the use of anticonvulsant agents to treat manic psychosis as well as being used as adjuncts to more traditional antipsychotic treatments for psychosis and schizophrenia; and the newest atypical antipsychotic ziprasidone. CME... |
 |
Medicines for Mental Health: The Ultimate Guide to Psychiatric Medication by Kevin Thompson PhD (Author) A finalist in the National Indie Excellence 2008 book awards, this book was written for anyone who suffers from sexual dysfunction, depression, bipolar disorder, or schizophrenia (or cares for someone who does). Medicines for Mental Health is the first book to provide detailed and readable information about all psychiatric medications, and other medical treatments, for these mental illnesses. Medicines cuts through jargon, demystifies mental illness, and explains how treatments work. It goes beyond current fads to cover important medications you need to know about, including many that will be new to your doctor. |
 |
Tarascon Rapid Reference Card: Antipsychotics and Anxiolytics by Dr.Joseph Esherick (Author), MD (Author) Measuring only 5.5 x 3.25 inches, this quick and handy laminated card tucks neatly into your Tarascon books to provide you with immediate access to the most frequently used tables in your Tarascon Pharmacopoeia or Pocketbook. |
 |
The Prescriber's Guide, Antipsychotics and Mood Stabilizers (Shahl's Essential Psychopharmacology) by Stephen M. Stahl (Author) In response to rapid developments in psychopharmacology, this is a spin-off from Stephen M. Stahl's new, completely revised and updated third edition of his much-acclaimed Prescriber's Guide. It covers the most important drugs in use today for psychosis and mood stabilization. In full color throughout, and with four or more pages for each of the antipsychotic drugs, Stephen M. Stahl distills his great expertise into a pragmatic formulary that gives all the information a prescriber needs to treat patients effectively. Each drug is covered in five categories: general therapeutics, dosing and use, side effects, special populations, and pearls. Target icons appear next to key categories for each drug so that the prescriber can go easily and instantly to the information needed. Several... |
| © 2009 BrightSurf.com |